[HTML][HTML] T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple …
JN Brudno, I Maric, SD Hartman, JJ Rose… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.gov
Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are
artificial proteins that target T cells to antigens. B-cell maturation antigen (BCMA) is
expressed by normal and malignant plasma cells but not normal essential cells. We
conducted the first-in-humans clinical trial, to our knowledge, of T cells expressing a CAR
targeting BCMA (CAR-BCMA).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are
artificial proteins that target T cells to antigens. B-cell maturation antigen (BCMA) is
expressed by normal and malignant plasma cells but not normal essential cells. We
conducted the first-in-humans clinical trial, to our knowledge, of T cells expressing a CAR
targeting BCMA (CAR-BCMA).
Abstract
Purpose
Therapies with novel mechanisms of action are needed for multiple myeloma (MM). T cells can be genetically modified to express chimeric antigen receptors (CARs), which are artificial proteins that target T cells to antigens. B-cell maturation antigen (BCMA) is expressed by normal and malignant plasma cells but not normal essential cells. We conducted the first-in-humans clinical trial, to our knowledge, of T cells expressing a CAR targeting BCMA (CAR-BCMA).
ncbi.nlm.nih.gov